Vicore Pharma Holding AB

Vicore Pharma Holding AB
About Us
Change country

Follow us:
Share:
Subscribe:

About Us

Vicore is a rare disease pharmaceutical company focused on rare lung disorders and related indications. The company currently has three drug development programs, VP01, VP02 and VP03.VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (“IPF”), pulmonary fibrosis in systemic sclerosis (“SSc”) and COVID-19. VP02 is based on a new formulation and delivery route of an existing immunomodulatory compound (an “IMiD”). VP02 focuses on the underlying disease and the severe cough associated with IPF. VP01 and VP02 are also being actively evaluated for other indications within the field of interstitial lung diseases which have a significant unmet need. VP03 includes follow-up molecules to VP01. The company's shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Vicore’s AIR study interim analysis suggests that C21 improves lung function in IPF patients

Thu, Feb 10, 2022 06:55 CET

· FVC increased by an average +251 ml over baseline at 24 weeks · Between 24 and 36 weeks, FVC was either stable or continued to increase · C21 was safe and well tolerated · Planning of a phase 2b study is being initiated · A webcast presentation will be held at 14:00 CET (8 AM EST) today with more study detailsGothenburg, February 10, 2022 - Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2 receptor (AT2R), today announces data from an interim analysis suggesting that C21 stabilizes

There are no items matching the current filter

There are no more items matching the current filter

Back to top

Share

About Us

Vicore’s AIR study interim analysis suggests that C21 improves lung function in IPF patients

Media